search
Back to results

"Manual Dexterity and Oculomotor Control in Schizophrenia" (MADOCS)

Primary Purpose

Schizophrenia

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Manual dexterity
Oculomotor movements
TMS coupled to EMG recording
Psychopathological evaluations
Neuropsychological evaluations
Sponsored by
Centre Hospitalier St Anne
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Schizophrenia focused on measuring Sensorimotor Integration, Schizophrenia, TMS, Oculomotor, Motor Control

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • All groups:

    1. 18>yrs<50
    2. Medical visit completed
    3. Visual acuity (9/10 for each eye or corrected)
    4. Provided written informed consent
  • Group of patient suffering from schizophrenia:

    4. DSM-IV-TR diagnostic criteria for schizophrenia 5. Treatment: stable atypical anti-psychotic medication for >3 months prior to the study

  • Group of UHR patient:

    6. 18>yrs<30 7. Fulfill at risk criteria of CAARMS diagnostic tool

Exclusion Criteria:

• All groups:

  1. IQ<70,
  2. Contraindications for TMS protocol: no previous history of neurosurgery or seizures or 1st degree relative with history of seizures, heart disease, drug abuse or addiction in the last 12 months, medications that lower seizure threshold including clozapine, bupropion, méthadone or theophylline.
  3. Metallic implant in head (except dental fillings)
  4. Pacemaker, or other electronic implanted devices
  5. Central neurological disease: parkinsonism, x
  6. Severe heart attack
  7. Instable clinical state (e.g. stroke)
  8. Previous history of drug abuse lasting more than 5 years or during the last year
  9. Life event with a moderate to severe impact
  10. Caffeine intake in the last two hours preceding visuomotor assessment

    • Groups of Siblings and Healthy controls:

  11. No previous history of psychiatric disease, psychotic spectrum disorder (according to DIGS 3.0)
  12. No previous history of antipsychotic medication (entire life)

    • Groups of UHR patient:

  13. Chlorpromazine dose >100mg over more than 12 weeks
  14. No previous history of autism spectrum disorder, bipolar disorder or diagnozed schizophrenia (according to DSM-IV-TR criteria), isolated anxiety disorders (e.g. social phobia, agoraphobia)

Sites / Locations

  • Centre de Recherche Clinique (CRC) - CHSARecruiting
  • Service Hospitalo-Universitaire (SHU) - CHSA

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Other

Other

Other

Other

Arm Label

Schizophrenia

Healthy sibling

Ultra high risk for developing Schizophrenia

Controls

Arm Description

40 patients with diagnosis of schizophrenia (25 medicated - 15 non-medicated)

25 healthy siblings

15 patients with ultra high risk for developing Schizophrenia

-25 age and gender-matched healthy controls

Outcomes

Primary Outcome Measures

Behavioural assessment
Index reflecting motor performance during visuomotor task (including force and oculomotor control)

Secondary Outcome Measures

Clinical scale : PANSS
Positive and Negative Syndrome Scale: Assess positive and negative symptoms
Clinical scale : DIGS III
Diagnostic Interview for Genetic Studies 3.0: Overview of clinical state
Clinical scale : BPRS
Brief Psychiatric Rating Scale: Assess schizophrenic symptoms
Clinical scale : SAS
Simpson Angus Extra-Pyramidal Scale: Asses extra-pyramidal signs
Clinical scale : AIMS
Abnormal Involuntary Movements Scale: Assess abnormal involuntary movements
Clinical scale : TAP
Test battery for Attentional Performance: Assess attentional capacity (e.g. working memory)
Clinical scale : Stroop
Stroop color naming test: Assess selective attention or inhibition.
Clinical scale : WASI
Wechsler Abbreviated Scale of Intelligence: Assess intelligence quotient
Tracking performance (motor task): RMS Error
RMS Error (Root Mean Square)
Tracking performance (motor task): Coefficient of variability
Coefficient of variability
Tracking performance (motor task): Timing
Timing/inhibition
Ocolomotor performance (eye tracker) : Saccade
Saccade error (back up/ catch up saccades) during smooth pursuit and fixation
Ocolomotor performance (eye tracker): Gain
Gain (target velocity/gaze velocity), Reaction time
Ocolomotor performance (eye tracker): Amplitude of eye movements
Amplitude (°) and velocity (°/s) of saccadic movements
Motor noise
Variability of EMG response during visuomotor task
Cortical excitability (MEP; TMS)
Motor evoked potential (MEP) during visuomotor task (single pulse TMS)
Cortical inhibition (SICI; TMS)
Cortical inhibition measured during visuomotor task (paired-pulse TMS; MEP)

Full Information

First Posted
May 20, 2016
Last Updated
October 18, 2017
Sponsor
Centre Hospitalier St Anne
Collaborators
University of Paris 5 - Rene Descartes, Institut National de la Santé Et de la Recherche Médicale, France
search

1. Study Identification

Unique Protocol Identification Number
NCT02826629
Brief Title
"Manual Dexterity and Oculomotor Control in Schizophrenia"
Acronym
MADOCS
Official Title
"MADOCS: Manual Dexterity and Oculomotor Control as Vulnerability Markers in Schizophrenia"
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Unknown status
Study Start Date
July 26, 2016 (Actual)
Primary Completion Date
September 2018 (Anticipated)
Study Completion Date
January 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier St Anne
Collaborators
University of Paris 5 - Rene Descartes, Institut National de la Santé Et de la Recherche Médicale, France

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators recently showed that visuomotor integration was significantly altered in schizophrenic patients during: (i) a grip force task (Teremetz et al., 2014), and (ii) a saccadic paradigm (oculomotor task)(Amado et al., 2008). Given this findings, the investigators propose a combined study of oculomotor and grip force control to better characterize the sensorimotor integration deficit. This approach may allow for identification of behavioural biomarkers of vulnerability to develop schizophrenia.
Detailed Description
1 - Scientific background and rational Use of sensory cues is essential for execution and correction of voluntary movements. The motor areas and their regulation is of special interest in patients with schizophrenia as there is clear evidence of motor abnormalities independent of the effects of antipsychotic medication, even before the onset of the disorder. Sensorimotor abnormalities have been proposed as a valid endophenotype in schizophrenia. Our global objective is to study and provide vulnerability markers for schizophrenia. Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM) Oculomotor movements during behavioral task will be recorded using a video-oculography device The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording 2 - Description of the project methodology There is strong evidence for schizophrenia being a neuro-developmental disorder (Rapoport et al., 2005). It has been shown, for many years, that patients with schizophrenia exhibit abnormal patterns of sensorimotor integration (Manschreck et al., 1982), which is the capacity to integrate different sensory stimuli into appropriate motor actions. It is clinically relevant, in terms of early diagnosis and prevention, whether deficient sensorimotor integration is present in the prodromal phase of schizophrenia, and whether this constitutes a vulnerability marker for the disease. Our global objective is to study the interactions and related substratum of oculomotor movements during force control task. The secondary objectives: (i) To show that increased motor noise is indeed present in schizophrenia. (ii) To show by TMS that cortical excitability in the primary motor cortex (M1) is task-modulated and decreased in schizophrenia. (iii) Assess the role of deficient cortical inhibition in these behavioral deficits To this end, three different groups of subjects will be studied: schizophrenic patients, non-affected siblings, ultra high risk patients, non-treated schizophrenic patients and healthy control subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
Sensorimotor Integration, Schizophrenia, TMS, Oculomotor, Motor Control

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
105 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Schizophrenia
Arm Type
Other
Arm Description
40 patients with diagnosis of schizophrenia (25 medicated - 15 non-medicated)
Arm Title
Healthy sibling
Arm Type
Other
Arm Description
25 healthy siblings
Arm Title
Ultra high risk for developing Schizophrenia
Arm Type
Other
Arm Description
15 patients with ultra high risk for developing Schizophrenia
Arm Title
Controls
Arm Type
Other
Arm Description
-25 age and gender-matched healthy controls
Intervention Type
Device
Intervention Name(s)
Manual dexterity
Intervention Description
Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)
Intervention Type
Device
Intervention Name(s)
Oculomotor movements
Intervention Description
Oculomotor movements during behavioral task will be recorded using a video-oculography device
Intervention Type
Device
Intervention Name(s)
TMS coupled to EMG recording
Intervention Description
The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording
Intervention Type
Other
Intervention Name(s)
Psychopathological evaluations
Intervention Type
Other
Intervention Name(s)
Neuropsychological evaluations
Primary Outcome Measure Information:
Title
Behavioural assessment
Description
Index reflecting motor performance during visuomotor task (including force and oculomotor control)
Time Frame
BASELINE
Secondary Outcome Measure Information:
Title
Clinical scale : PANSS
Description
Positive and Negative Syndrome Scale: Assess positive and negative symptoms
Time Frame
BASELINE
Title
Clinical scale : DIGS III
Description
Diagnostic Interview for Genetic Studies 3.0: Overview of clinical state
Time Frame
BASELINE
Title
Clinical scale : BPRS
Description
Brief Psychiatric Rating Scale: Assess schizophrenic symptoms
Time Frame
BASELINE
Title
Clinical scale : SAS
Description
Simpson Angus Extra-Pyramidal Scale: Asses extra-pyramidal signs
Time Frame
BASELINE
Title
Clinical scale : AIMS
Description
Abnormal Involuntary Movements Scale: Assess abnormal involuntary movements
Time Frame
BASELINE
Title
Clinical scale : TAP
Description
Test battery for Attentional Performance: Assess attentional capacity (e.g. working memory)
Time Frame
BASELINE
Title
Clinical scale : Stroop
Description
Stroop color naming test: Assess selective attention or inhibition.
Time Frame
BASELINE
Title
Clinical scale : WASI
Description
Wechsler Abbreviated Scale of Intelligence: Assess intelligence quotient
Time Frame
BASELINE
Title
Tracking performance (motor task): RMS Error
Description
RMS Error (Root Mean Square)
Time Frame
BASELINE
Title
Tracking performance (motor task): Coefficient of variability
Description
Coefficient of variability
Time Frame
BASELINE
Title
Tracking performance (motor task): Timing
Description
Timing/inhibition
Time Frame
BASELINE
Title
Ocolomotor performance (eye tracker) : Saccade
Description
Saccade error (back up/ catch up saccades) during smooth pursuit and fixation
Time Frame
BASELINE
Title
Ocolomotor performance (eye tracker): Gain
Description
Gain (target velocity/gaze velocity), Reaction time
Time Frame
BASELINE
Title
Ocolomotor performance (eye tracker): Amplitude of eye movements
Description
Amplitude (°) and velocity (°/s) of saccadic movements
Time Frame
BASELINE
Title
Motor noise
Description
Variability of EMG response during visuomotor task
Time Frame
BASELINE
Title
Cortical excitability (MEP; TMS)
Description
Motor evoked potential (MEP) during visuomotor task (single pulse TMS)
Time Frame
BASELINE
Title
Cortical inhibition (SICI; TMS)
Description
Cortical inhibition measured during visuomotor task (paired-pulse TMS; MEP)
Time Frame
BASELINE

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All groups: 18>yrs<50 Medical visit completed Visual acuity (9/10 for each eye or corrected) Provided written informed consent Group of patient suffering from schizophrenia: 4. DSM-IV-TR diagnostic criteria for schizophrenia 5. Treatment: stable atypical anti-psychotic medication for >3 months prior to the study Group of UHR patient: 6. 18>yrs<30 7. Fulfill at risk criteria of CAARMS diagnostic tool Exclusion Criteria: • All groups: IQ<70, Contraindications for TMS protocol: no previous history of neurosurgery or seizures or 1st degree relative with history of seizures, heart disease, drug abuse or addiction in the last 12 months, medications that lower seizure threshold including clozapine, bupropion, méthadone or theophylline. Metallic implant in head (except dental fillings) Pacemaker, or other electronic implanted devices Central neurological disease: parkinsonism, x Severe heart attack Instable clinical state (e.g. stroke) Previous history of drug abuse lasting more than 5 years or during the last year Life event with a moderate to severe impact Caffeine intake in the last two hours preceding visuomotor assessment • Groups of Siblings and Healthy controls: No previous history of psychiatric disease, psychotic spectrum disorder (according to DIGS 3.0) No previous history of antipsychotic medication (entire life) • Groups of UHR patient: Chlorpromazine dose >100mg over more than 12 weeks No previous history of autism spectrum disorder, bipolar disorder or diagnozed schizophrenia (according to DSM-IV-TR criteria), isolated anxiety disorders (e.g. social phobia, agoraphobia)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Isabelle Amado, Dr
Phone
00 33 1 45 65 81 79
Email
i.amado@ch-sainte-anne.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Marie GODARD
Phone
00 33 1 45 65 77 28
Email
marie.godard@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Isabelle Amado, Dr
Organizational Affiliation
CHSA
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Pavel Lindberg, PhD
Organizational Affiliation
Institut National de la Santé Et de la Recherche Médicale, France
Official's Role
Study Director
Facility Information:
Facility Name
Centre de Recherche Clinique (CRC) - CHSA
City
Paris
ZIP/Postal Code
75014
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Macarena CUENCA
Email
m.cuenca@ch-sainte-anne.fr
First Name & Middle Initial & Last Name & Degree
Cecile Bergot
Phone
00 33 1 45 65 84 90
Email
c.bergot@ch-sainte-anne.fr
First Name & Middle Initial & Last Name & Degree
Macarena CUENCA
Facility Name
Service Hospitalo-Universitaire (SHU) - CHSA
City
Paris
ZIP/Postal Code
75014
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabelle Amado
Phone
00 33 1 45 65 81 79
Email
i.amado@ch-sainte-anne.fr
First Name & Middle Initial & Last Name & Degree
Marie GODARD
Phone
00 33 1 45 65 77 28
Email
marie.godard@aphp.fr
First Name & Middle Initial & Last Name & Degree
Isabelle Amado

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25369465
Citation
Teremetz M, Amado I, Bendjemaa N, Krebs MO, Lindberg PG, Maier MA. Deficient grip force control in schizophrenia: behavioral and modeling evidence for altered motor inhibition and motor noise. PLoS One. 2014 Nov 4;9(11):e111853. doi: 10.1371/journal.pone.0111853. eCollection 2014.
Results Reference
background
PubMed Identifier
18197268
Citation
Amado I, Landgraf S, Bourdel MC, Leonardi S, Krebs MO. Predictive saccades are impaired in biological nonpsychotic siblings of schizophrenia patients. J Psychiatry Neurosci. 2008 Jan;33(1):17-22.
Results Reference
background

Learn more about this trial

"Manual Dexterity and Oculomotor Control in Schizophrenia"

We'll reach out to this number within 24 hrs